The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
Introduction: Acute lymphoblastic leukemia (ALL) is characterized by the uncontrolled proliferation of lymphoid precursor cells, most from the B phenotype, which is the result of various cytogenetic mutations and alterations involved in cell division and survival. Objective: To evaluate the efficacy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2025-07-01
|
| Series: | Revista Médica del Hospital General de México |
| Subjects: | |
| Online Access: | https://www.hospitalgeneral.mx/frame_eng.php?id=260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849254149930090496 |
|---|---|
| author | Camila Terreros-Palacios Daniela Pérez-Sámano Adán G. Gallardo-Rodríguez Irma Olarte-Carrillo Carlos Martínez-Murillo Gilberto I. Barranco-Lampon Christian Ramos-Peñafiel |
| author_facet | Camila Terreros-Palacios Daniela Pérez-Sámano Adán G. Gallardo-Rodríguez Irma Olarte-Carrillo Carlos Martínez-Murillo Gilberto I. Barranco-Lampon Christian Ramos-Peñafiel |
| author_sort | Camila Terreros-Palacios |
| collection | DOAJ |
| description | Introduction: Acute lymphoblastic leukemia (ALL) is characterized by the uncontrolled proliferation of lymphoid precursor cells, most from the B phenotype, which is the result of various cytogenetic mutations and alterations involved in cell division and survival. Objective: To evaluate the efficacy of bortezomib in patients with ALL through the measurable residual disease (MRD) outcome at 6 weeks (day +45) and response to induction therapy with chemotherapy in combination with a first-generation proteasome inhibitor. Material and methods: This was cross-sectional, observational, retrospective, and analytical study based on clinical records of patients diagnosed with ALL who received induction therapy plus bortezomib, from January 1, 2019, to May 31, 2024, and comparing it to a historic group. Results: Twenty patients were included, 60% (n = 12) of whom were male, with an average age of 26 years (range 18-61 years). All cases corresponded to the B phenotype, 85% were negative for BCR: ABL1, without central nervous system infiltration (CNS). After treatment initiation, the most common adverse event was anemia and thrombocytopenia (GIII-GIV) and 30% experienced grade I-II peripheral neuropathy. When compared to the historical record, the odds ratio (OR) to evaluate the treatment response with early response variables, there was no difference (confidence interval [CI] = 0.173-1.630, p = 0.206). In overall survival, there were no statistically significant differences when compared with the historical cohort, OR of 1.538 (CI = 0.502-4.748, p = 0.319). Conclusion: The addition of bortezomib to the induction chemotherapy did not show a benefit in the percentage of remissions or the proportion of MRD. It is important to continue exploring new options that can be added to this high-risk group of patients to reduce refractoriness and the proportion of early relapses.
|
| format | Article |
| id | doaj-art-90104015d34c440694ec0a1b2e92e8aa |
| institution | Kabale University |
| issn | 0185-1063 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Revista Médica del Hospital General de México |
| spelling | doaj-art-90104015d34c440694ec0a1b2e92e8aa2025-08-20T03:56:08ZengPermanyerRevista Médica del Hospital General de México0185-10632025-07-01883The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemiaCamila Terreros-Palacios0Daniela Pérez-Sámano1Adán G. Gallardo-Rodríguez2Irma Olarte-Carrillo3Carlos Martínez-Murillo4Gilberto I. Barranco-Lampon5Christian Ramos-Peñafiel6Department of Hematology. MexicoDepartment of Hematology. MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoMolecular Biology Laboratory, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoHematology Service, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Secretaría de Salud, Mexico City, MexicoIntroduction: Acute lymphoblastic leukemia (ALL) is characterized by the uncontrolled proliferation of lymphoid precursor cells, most from the B phenotype, which is the result of various cytogenetic mutations and alterations involved in cell division and survival. Objective: To evaluate the efficacy of bortezomib in patients with ALL through the measurable residual disease (MRD) outcome at 6 weeks (day +45) and response to induction therapy with chemotherapy in combination with a first-generation proteasome inhibitor. Material and methods: This was cross-sectional, observational, retrospective, and analytical study based on clinical records of patients diagnosed with ALL who received induction therapy plus bortezomib, from January 1, 2019, to May 31, 2024, and comparing it to a historic group. Results: Twenty patients were included, 60% (n = 12) of whom were male, with an average age of 26 years (range 18-61 years). All cases corresponded to the B phenotype, 85% were negative for BCR: ABL1, without central nervous system infiltration (CNS). After treatment initiation, the most common adverse event was anemia and thrombocytopenia (GIII-GIV) and 30% experienced grade I-II peripheral neuropathy. When compared to the historical record, the odds ratio (OR) to evaluate the treatment response with early response variables, there was no difference (confidence interval [CI] = 0.173-1.630, p = 0.206). In overall survival, there were no statistically significant differences when compared with the historical cohort, OR of 1.538 (CI = 0.502-4.748, p = 0.319). Conclusion: The addition of bortezomib to the induction chemotherapy did not show a benefit in the percentage of remissions or the proportion of MRD. It is important to continue exploring new options that can be added to this high-risk group of patients to reduce refractoriness and the proportion of early relapses. https://www.hospitalgeneral.mx/frame_eng.php?id=260Acute lymphoblastic leukemia. Bortezomib. Measurable residual disease. Complete remission. Overall survival. |
| spellingShingle | Camila Terreros-Palacios Daniela Pérez-Sámano Adán G. Gallardo-Rodríguez Irma Olarte-Carrillo Carlos Martínez-Murillo Gilberto I. Barranco-Lampon Christian Ramos-Peñafiel The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia Revista Médica del Hospital General de México Acute lymphoblastic leukemia. Bortezomib. Measurable residual disease. Complete remission. Overall survival. |
| title | The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia |
| title_full | The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia |
| title_fullStr | The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia |
| title_full_unstemmed | The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia |
| title_short | The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia |
| title_sort | efficacy of bortezomib during induction therapy in patients with high risk acute lymphoblastic leukemia |
| topic | Acute lymphoblastic leukemia. Bortezomib. Measurable residual disease. Complete remission. Overall survival. |
| url | https://www.hospitalgeneral.mx/frame_eng.php?id=260 |
| work_keys_str_mv | AT camilaterrerospalacios theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT danielaperezsamano theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT adanggallardorodriguez theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT irmaolartecarrillo theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT carlosmartinezmurillo theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT gilbertoibarrancolampon theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT christianramospenafiel theefficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT camilaterrerospalacios efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT danielaperezsamano efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT adanggallardorodriguez efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT irmaolartecarrillo efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT carlosmartinezmurillo efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT gilbertoibarrancolampon efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia AT christianramospenafiel efficacyofbortezomibduringinductiontherapyinpatientswithhighriskacutelymphoblasticleukemia |